Healthcare / BiotechnologyTaipei Exchange
$15.30
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-312.8M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35.3%
↓Gross Margin
-103.2%
↓Debt/Equity
1.08
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+65.7%
FCF CAGR
—
FCF margin
-395.4%
FCF / Net income
1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $107.5M · net income $-389.0M · FCF $-425.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $107.5M | $107.5M | $39.8M | $25.8M | $23.6M |
| Net Income | $-389.0M | $-389.0M | $-368.2M | $-338.0M | $-327.9M |
| EBITDA | $-257.4M | $-257.4M | $-246.7M | $-219.6M | $-219.5M |
| EPS | — | — | -2.68 | -2.76 | -2.77 |
| Gross Margin | -103.2% | -103.2% | -396.3% | -634.5% | -622.8% |
| Operating Margin | -339.0% | -339.0% | -895.3% | -1239.9% | -1345.1% |
| Net Margin | -361.8% | -361.8% | -925.6% | -1307.6% | -1386.5% |
| Balance Sheet | |||||
| Debt/Equity | 1.08 | 1.08 | 1.46 | 1.23 | 1.37 |
| Current Ratio | 0.96 | 0.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-425.1M | $-425.1M | $-312.8M | $-234.3M | $-201.4M |
| Returns | |||||
| ROE | -35.3% | -35.3% | -45.2% | -28.9% | -31.8% |
| Valuation | |||||
| P/B | 2.48 | 2.48 | 4.50 | 3.16 | 3.66 |
| Growth & Yield | |||||
| Revenue Growth | 170.3% | 170.3% | 53.9% | 9.3% | — |
| EPS Growth | — | — | 3.0% | 0.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.68 → n/d
Residual
-18.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.